Clarivate backs FY25 adjusted EPS view 60c-70c, consensus 65c

Backs FY25 revenue view $2.28B-$2.4B, consensus $2.36B. Backs FY25 adjusted EBITDA view $940M-$1B. Backs FY25 free cash flow $300M-$380M. “During the first half of 2025, we achieved enhanced performance, primarily driven by growth in organic ACV within the Academia & Government and Life Sciences & Healthcare segments and in organic subscription revenue within A&G,” said Jonathan Collins, executive VP and CFO. “With revenue for the first half meeting our projections and continued strong cost management, we are reaffirming our outlook for the full year 2025.”